No profile data available.
BioNTech SE (BNTX) is a healthcare company in the antiviral pharmaceuticals industry, based in Mainz, Germany, with about 7,807 full-time employees.
It reported revenue of 2.87 billion EUR for fiscal year 2025, up 4.3% from fiscal year 2024, and net income of -1.14 billion EUR. In Q2 2026 (the quarter ended June 30, 2026) revenue was 105.60 million EUR, down 59.5% from a year before. United States was its largest region in fiscal year 2025, with 63% of revenue. Its market capitalization was $24.36 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
BioNTech reported 2.87 billion EUR in revenue for fiscal year 2025, up 4.3% from 2.75 billion EUR in fiscal year 2024. In Q2 2026 revenue was 105.60 million EUR.
United States: 63% of revenue by region in fiscal year 2025, followed by Germany (26%).
$24.36 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Novavax, Inc. (NVAX), Vir Biotechnology, Inc. (VIR).